Top Markets
Coin of the day
Alimera Sciences, Inc. Alimera Sciences, Inc.

Alimera Sciences, Inc.

ALIM
Kedudukan dalam Saham #26668
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and... Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular edema (DME), a severe retinal disease in individuals with diabetes that can lead to profound vision loss and blindness. Additionally, ILUVIEN helps prevent relapses of recurrent non-infectious uveitis affecting the posterior segment of the eye. The company distributes its products directly and through distributors to various healthcare entities such as physician offices, pharmacies, and hospitals. Alimera also maintains a collaboration with EyePoint Pharmaceuticals US, Inc. focused on developing and marketing insert technology. This technology is designed to deliver corticosteroids to the back of the eye for treating and preventing various human eye diseases, including diabetic macular edema. Founded in 2003, Alimera Sciences is headquartered in Alpharetta, Georgia.
Harga Saham
$5.54
Disegerakkan terakhir: 2024-09-18
Modal Pasaran
$38.76M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Alimera Sciences, Inc. (ALIM)

Kategori

Nisbah P/B bagi Alimera Sciences, Inc. (ALIM)
Nisbah P/B pada August 2026 TTM: 3.07
Menurut laporan kewangan dan harga saham terkini Alimera Sciences, Inc., nisbah P/B semasa (TTM) ialah 3.07. Pada akhir 2022, nisbah P/B syarikat ialah -0.91.
Sejarah nisbah P/B untuk Alimera Sciences, Inc. dari 2006 hingga 2026
Nisbah P/B pada akhir setiap tahun
Tahun Nisbah P/B Ubah
2026 (TTM) 3.07 28.33%
2023 2.39 -362.98%
2022 -0.91 -93.00%
2021 -12.99 379.74%
2020 -2.71 -66.72%
2019 -8.13 -135.04%
2018 23.22 288.76%
2017 5.97 167.96%
2016 2.23 -45.46%
2015 4.09 -9.57%
2014 4.52 -115.00%
2013 -30.13 -2,488.44%
2012 1.26 -19.62%
2011 1.57 -78.14%
2010 7.18 -331.53%
2009 -3.10 1,917.76%
2008 -0.15 -58.80%
2007 -0.37 -21.65%
2006 -0.48 0.00%
Nisbah P/B untuk syarikat atau pesaing yang serupa